Stock Analysis of Atara Biotherapeutics Inc (ATRA) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ATRA
Close 0.710
Change 0.100 / 16.39 %
Volume 1836.01 K
Vol Change 11246.00 / 0.616 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Atara Biotherapeutics Inc
PE (TTM)

-0.347

Very Poor
Price / Book

-2.30

Very Poor
Price / Sales

2.39

Not Good
Piotroski F Score

2.0

Poor
Market Cap

85495.36 K

Enterprise Value

71833.36 K

ROA (TTM)

-109.12

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

-687.41

Very Poor
Revenue

92.86 %

4542.00 K
Net Profit

27.13 %

-290248.00 K
Debt to Equity

-0.123

Very Poor
Altman Z Score

-22.51

Very Poor
Quick Ratio

0.648

Not Good
Cash Ratio

0.364

Poor


Highs/Lows of Atara Biotherapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.5564 27.61 % 1.66 % 0.7190.556420-May-2414-May-24
Two Week0.6298 12.73 % 2.46 % 0.7190.484320-May-2413-May-24
One Month0.661 7.41 % 6.86 % 0.760.484301-May-2413-May-24
Three Month0.8404 15.52 % 6.69 % 0.93750.484329-Feb-2413-May-24
Six Months0.558 27.24 % 16.73 % 1.580.432302-Feb-2403-Jan-24
One year2.11 66.35 % 26.63 % 2.5350.198604-Aug-2313-Nov-23
Two year5.16 86.24 % 36.06 % 5.640.198606-Feb-2313-Nov-23
Five year23.47 96.97 % 86.89 % 5.640.198606-Feb-2313-Nov-23


Technical View of Atara Biotherapeutics Inc
RSI

57.84

Neutral
MACD

-0.0189

Strong Bullish
ADX

15.29

Mild Bullish
Super Trend

0.721

Mild Bearish
Williams %R

-18.14

Mild Bearish
CCI

44.87

Neutral


EMA 5

0.639

Strong Bullish
EMA 15

0.630

Whipsaw
EMA 50

0.672

Strong Bullish
EMA 100

0.751

Mild Bearish
SMA 100

0.693

Whipsaw
SMA 200

0.965

Mild Bearish
SMA 5 / 20

0.634 / 0.642

Mild Bearish
SMA 15 / 50

0.620 / 0.675

Strong Bearish
SMA 50 / 200

0.675 / 0.965

Mild Bearish




Charts of Atara Biotherapeutics Inc


Returns of Atara Biotherapeutics Inc with Peers
Period / StockATRAALVRCMRXSLS
1 Week27.61%2.51%-6.12%8.03%
1 Mth7.41%2.49%11.45%-3.90%
3 Mth-15.52%9.25%-19.20%84.29%
6mth27.24%-53.12%-1.43%50.77%
1 Year-66.35%-81.65%-18.54%-15.43%
2 Year-86.24%-80.23%-58.06%-57.23%
5 Years-96.97%--71.09%-96.21%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Atara Biotherapeutics Inc with Peers
Ratio / StockATRAALVRCMRXSLS
PE-0.347-101.68-265.10-586.69
P/B-2.30103.23105.286609.42
ROA-109.12-80.87-36.49-206.77
ROE0-101.52-39.71-1126.57
Debt To Equity-0.1230.0740.0050-0.056
Revenue4542.00 K
92.86 % 		0
% 		1134.00 K
96.65 % 		0
100.00 %
Net Income-290248.00 K
27.13 % 		-168858.00 K
0.088 % 		-84894.00 K
149.31 % 		-38325.00 K
7.21 %


Technicals of Atara Biotherapeutics Inc with Peers
Technical / StockATRAALVRCMRXSLS-
ADX15.2932.9013.8521.70
CMF-0.0660.3520.125-0.0081
MFI38.7128.5565.4281.43
RSI57.8448.6051.1260.21
MACD Abv SignalTrueFalseTrueTrue
Price Above 50 MATrueTrueFalseTrue-
Price Above 200 MAFalseFalseFalseTrue-


About : Atara Biotherapeutics Inc

Address : 2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320
Tel : 805 623 4211
URL : https://www.atarabio.com
Code : ATRA, ISIN : US0465131078, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 16_Oct_2014
Employee Count : 173

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)